Farabi Pharmaceutical (XTEH:DFRB1) Buyback Yield %: 0.00 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Farabi Pharmaceutical Buyback Yield %?

Farabi Pharmaceutical XTEH:DFRB1 Buyback Yield % is 0.00 as of Jul. 22, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Farabi Pharmaceutical's current buyback yield was 0.00%.

Farabi Pharmaceutical Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical Buyback Yield % Chart

Farabi Pharmaceutical Annual Data
Trend
Buyback Yield %

Farabi Pharmaceutical Quarterly Data
Buyback Yield %

XTEH:DFRB1 vs IMNPQ, INNV: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farabi Pharmaceutical Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Farabi Pharmaceutical's Buyback Yield % falls into.


Farabi Pharmaceutical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Farabi Pharmaceutical's Buyback Yield for the fiscal year that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- ( + ) /
=N/A%

Farabi Pharmaceutical's annualized Buyback Yield for the quarter that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- ( + ) /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Buyback Yield % of 0.00 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Buyback Yield % too high?
Farabi Pharmaceutical's current Buyback Yield % is 0.00.
How does Farabi Pharmaceutical's Buyback Yield % compare to IMNPQ and INNV?
Farabi Pharmaceutical's Buyback Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Buyback Yield % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.